Cerebrospinal fluid biomarkers of Alzheimer's disease

+ 作者地址


0
  • 参考文献
  • 相关文章
  • 统计

[1] Apostolova LG;Hwang KS;Andrawis JP;Green AE;Babakchanian S;Morra JH;Cummings JL;Toga AW;Trojanowski JQ;Shaw LM;Jack CR Jr;Petersen RC;Aisen PS;Jagust WJ;Koeppe RA;Mathis CA;Weiner MW;Thompson PM .3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects.[J].Neurobiology of Aging: Experimental and Clinical Research,2010(8):1284-1303.

[7] Esteban-Santillan C;Praditsuwan R;Ueda H;Geldmacher DS .Clock drawing test in very mild Alzheimer's disease.[J].Journal of the American Geriatrics Society,1998(10):1266-1269.

[12] Pallas M;Camins A .Molecular and biochemical features in Alzheimer's disease.[J].Current pharmaceutical design,2006(33):4389-4408.

[13] Pappas BA;Bayley PJ;Bui BK;Hansen LA;Thal LJ .Choline acetyltransferase activity and cognitive domain scores of Alzheimer's patients.[J].Neurobiology of Aging: Experimental and Clinical Research,2000(1):11-17.

[16] Ray S;Reddy PJ;Jain R;Gollapalli K;Moiyadi A;Srivastava S .Proteomic technologies for the identification of disease biomarkers in serum: advances and challenges ahead.[J].Proteomics,2011(11):2139-2161.

[18] Richard J. Perrin;Anne M. Fagan;David M. Holtzman .Multimodal techniques for diagnosis and prognosis of Alzheimer's disease[J].Nature,2009(Oct.15 TN.7266):916-922.

[20] Blennow K .CSF biomarkers for Alzheimer's disease: use in early diagnosis and evaluation of drug treatment.[J].Expert Review of Molecular Diagnostics,2005(5):661-672.

[21] Evin G;Weidemann A .Biogenesis and metabolism of Alzheimer's disease Abeta amyloid peptides.[J].Peptides: An International Journal,2002(7):1285-1297.

[25] Masters CL;Cappai R;Barnham KJ;Villemagne VL .Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics.[J].Journal of Neurochemistry: Offical Journal of the International Society for Neurochemistry,2006(6):1700-1725.

[26] McLean,CA;Cherny,RA;Fraser,FW;Fuller,SJ;Smith,MJ;Beyreuther,K;Bush,AI;Masters,CL .Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease.[J].Annals of Neurology,1999(6):860-866.

[28] Brouillette,J.;Caillierez,R.;Zommer,N.;Alves-Pires,C.;Benilova,I.;Blum,D.;deStrooper,B.;Buée,L. .Neurotoxicity and memory deficits induced by soluble low-molecular-weight amyloid-β 1-42 oligomers are revealed in vivo by using a novel animal model[J].The Journal of Neuroscience: The Official Journal of the Society for Neuroscience,2012(23):7852-7861.

[29] Watts, J.C.;Giles, K.;Grillo, S.K.;Lemus, A.;DeArmond, S.J.;Prusiner, S.B. .Bioluminescence imaging of Aβ deposition in bigenic mouse models of alzheimer's disease[J].Proceedings of the National Academy of Sciences of the United States of America,2011(6):2528-2533.

[31] Lannfelt L;Basun H;Vigo Pelfrey C;Wahlund LO;Winblad B;Lieberburg I;Schenk D .Amyloid beta-peptide in cerebrospinal fluid in individuals with the Swedish Alzheimer amyloid precursor protein mutation.[J].Neuroscience Letters: An International Multidisciplinary Journal Devoted to the Rapid Publication of Basic Research in the Brain Sciences,1995(3):203-206.

[32] Southwick PC;Yamagata SK;Echols CL Jr;Higson GJ;Neynaber SA;Parson RE;Munroe WA .Assessment of amyloid beta protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease.[J].Journal of Neurochemistry: Offical Journal of the International Society for Neurochemistry,1996(1):259-265.

[33] van Gool WA;Kuiper MA;Walstra GJ;Wolters EC;Bolhuis PA .Concentrations of amyloid beta protein in cerebrospinal fluid of patients with Alzheimer's disease.[J].Annals of Neurology,1995(2):277-279.

[34] Andreasen N;Hesse C;Davidsson P;Minthon L;Wallin A;Winblad B;Vanderstichele H;Vanmechelen E;Blennow K .Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease (see comments)[J].Archives of Neurology,1999(6):673-680.

[35] Blennow K;Hampel H .CSF markers for incipient Alzheimer's disease.[J].Lancet Neurology,2003(10):605-613.

[36] Holmes,C;Boche,D;Wilkinson,D;Yadegarfar,G;Hopkins,V;Bayer,A;Jones,RW;Bullock,R;Love,S;Neal,JW;Zotova,E;Nicoll,JA .Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial.[J].The Lancet,2008(9634):216-223.

[37] Clark CM;Xie S;Chittams J;Ewbank D;Peskind E;Galasko D;Morris JC;McKeel DW Jr;Farlow M;Weitlauf SL;Quinn J;Kaye J;Knopman D;Arai H;Doody RS;DeCarli C;Leight S;Lee VM;Trojanowski JQ .Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?[J].Archives of Neurology,2003(12):1696-1702.

[38] Engelborghs S;De-Vreese K;Van-de-Casteele T;Vanderstichele H;Van-Everbroeck B;Cras P;Martin JJ;Vanmechelen E;De-Deyn PP .Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia.[J].Neurobiology of Aging: Experimental and Clinical Research,2008(8):1143-1159.

[39] Fagan AM;Roe CM;Xiong C;Mintun MA;Morris JC;Holtzman DM .Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.[J].Archives of Neurology,2007(3):343-349.

[40] Galasko D;Chang L;Motter R;Clark CM;Kaye J;Knopman D;Thomas R;Kholodenko D;Schenk D;Lieberburg I;Miller B;Green R;Basherad R;Kertiles L;Boss MA;Seubert P .High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.[J].Archives of Neurology,1998(7):937-945.

[41] Hulstaert F;Blennow K;Ivanoiu A;Schoonderwaldt HC;Riemenschneider M;De Deyn-PP;Bancher C;Cras P;Wiltfang J;Mehta PD;Iqbal K;Pottel H;Vanmechelen E;Vanderstichele H .Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF (see comments)[J].Neurology: Official Journal of the American Academy of Neurology,1999(8):1555-1562.

[42] Ida N;Hartmann T;Pantel J;Schroder J;Zerfass R;Forstl H;Sandbrink R;Masters CL;Beyreuther K .Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay.[J].The Journal of biological chemistry,1996(37):22908-22914.

[44] Kapaki E;Kilidireas K;Paraskevas GP;Michalopoulou M;Patsouris E .Highly increased CSF tau protein and decreased beta-amyloid (1-42) in sporadic CJD: a discrimination from Alzheimer's disease?[J].Journal of Neurology, Neurosurgery and Psychiatry,2001(3):401-403.

[45] Lewczuk P;Esselmann H;Otto M;Maler JM;Henkel AW;Henkel MK;Eikenberg O;Antz C;Krause WR;Reulbach U;Kornhuber J;Wiltfang J .Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau.[J].Neurobiology of Aging: Experimental and Clinical Research,2004(3):273-281.

[46] Mehta PD;Pirttila T;Mehta SP;Sersen EA;Aisen PS;Wisniewski HM .Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease.[J].Archives of Neurology,2000(1):100-105.

[51] Andreasen N;Blennow K .beta-Amyloid (Abeta) protein in cerebrospinal fluid as a biomarker for Alzheimer's disease.[J].Peptides: An International Journal,2002(7):1205-1214.

[55] Shoji M;Matsubara E;Kanai M;Watanabe M;Nakamura T;Tomidokoro Y;Shizuka M;Wakabayashi K;Igeta Y;Ikeda Y;Mizushima K;Amari M;Ishiguro K;Kawarabayashi T;Harigaya Y;Okamoto K;Hirai S .Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease.[J].Journal of the Neurological Sciences: Official Bulletin of the World Federation of Neurology,1998(2):134-140.

[58] Hampel H;Teipel SJ;Fuchsberger T;Andreasen N;Wiltfang J;Otto M;Shen Y;Dodel R;Du Y;Farlow M;Moller HJ;Blennow K;Buerger K .Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.[J].Molecular psychiatry,2004(7):705-710.

[59] Hu YY;He SS;Wang X;Duan QH;Grundke Iqbal I;Iqbal K;Wang J .Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients : an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay.[J].American Journal of Pathology,2002(4):1269-1278.

[60] Mattsson N;Zetterberg H;Hansson O .CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.[J].JAMA,2009(4):385-393.

[61] Hampel H;Buerger K;Zinkowski R;Teipel SJ;Goernitz A;Andreasen N;Sjoegren M;DeBernardis J;Kerkman D;Ishiguro K;Ohno H;Vanmechelen E;Vanderstichele H;McCulloch C;Moller HJ;Davies P;Blennow K .Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.[J].Archives of General Psychiatry,2004(1):95-102.

[62] Brys M;Pirraglia E;Rich K;Rolstad S;Mosconi L;Switalski R;Glodzik Sobanska L;De Santi S;Zinkowski R;Mehta P;Pratico D;Saint Louis LA;Wallin A;Blennow K;de Leon MJ .Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment.[J].Neurobiology of Aging: Experimental and Clinical Research,2009(5):682-690.

[63] Itoh,N;Arai,H;Urakami,K;Ishiguro,K;Ohno,H;Hampel,H;Buerger,K;Wiltfang,J;Otto,M;Kretzschmar,H;Moeller,HJ;Imagawa,M;Kohno,H;Nakashima,K;Kuzuhara,S;Sasaki,H;Imahori,K .Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease.[J].Annals of Neurology,2001(2):150-156.

[65] Buerger K;Zinkowski R;Teipel SJ;Tapiola T;Arai H;Blennow K;Andreasen N;Hofmann Kiefer K;DeBernardis J;Kerkman D;McCulloch C;Kohnken R;Padberg F;Pirttila T;Schapiro MB;Rapoport SI;Moller HJ;Davies P;Hampel H .Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231.[J].Archives of Neurology,2002(8):1267-1272.

[66] Hu YuanYuan;He ShanShu;Wang XiaoChuang;Duan QiuHong;Khatoon Sabiha;Iqbal Khalid;Grundke-Iqbal Inge;Wang JianZhi .Elevated levels of phosphorylated neurofilament proteins in cerebrospinal fluid of Alzheimer disease patients.[J].Neuroscience Letters: An International Multidisciplinary Journal Devoted to the Rapid Publication of Basic Research in the Brain Sciences,2002(3):156-160.

[67] Shaw LM;Vanderstichele H;Knapik-Czajka M;Clark CM;Aisen PS;Petersen RC;Blennow K;Soares H;Simon A;Lewczuk P;Dean R;Siemers E;Potter W;Lee VM;Trojanowski JQ .Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.[J].Annals of neurology,2009(4):403-413.

[68] Mulder C;Verwey NA;van der Flier WM;Bouwman FH;Kok A;van Elk EJ;Scheltens P;Blankenstein MA .Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease.[J].Clinical Chemistry,2010(2):248-253.

[70] Soraia Barao;Lujia Zhou;Katarzyna Adamczuk;Tine Vanhoutvin;Fred van Leuven;David Demedts;Anne-Catherine Vijverman;Xavier Bossuyt;Rik Vandenberghe;Bart De Strooper .BACE1 Levels Correlate with Phospho-Tau Levels in Human Cerebrospinal Fluid.[J].Current Alzheimer research,2013(7):671-678.

[71] Mulder SD;van der Flier WM;Verheijen JH;Mulder C;Scheltens P;Blankenstein MA;Hack CE;Veerhuis R .BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology.[J].Journal of Alzheimer's disease,2010(1):253-260.

[73] Verwey NA;Kester MI;van der Flier WM;Veerhuis R;Berkhof H;Twaalfhoven H;Blankenstein MA;Scheltens And P;Pijnenburg YA .Additional value of CSF amyloid-beta 40 levels in the differentiation between FTLD and control subjects.[J].Journal of Alzheimer's disease: JAD,2010(2):445-452.

[74] Bibl,M.;Gallus,M.;Welge,V.;Esselmann,H.;Wolf,S.;Rüther,E.;Wiltfang,J. .Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer's, but not in frontotemporal dementia[J].Journal of neural transmission,2012(7):805-813.

[75] Ikeuchi T;Hirayama S;Miida T;Fukamachi I;Tokutake T;Ebinuma H;Takubo K;Kaneko H;Kasuga K;Kakita A;Takahashi H;Bujo H;Saito Y;Nishizawa M .Increased levels of soluble LR11 in cerebrospinal fluid of patients with Alzheimer disease.[J].Dementia and geriatric cognitive disorders,2010(1):28-32.

[76] Laske C;Stransky E;Hoffmann N;Maetzler W;Straten G;Eschweiler GW;Leyhe T .Macrophage colony-stimulating factor (M-CSF) in plasma and CSF of patients with mild cognitive impairment and Alzheimer's disease.[J].Current Alzheimer research,2010(5):409-414.

[78] Yin GN;Lee HW;Cho JY.Neuronal pentraxin receptor in cerebrospinal fluid as a potential biomarker for neurodegenerative diseases.[J].Brain research,2009:158-170.

[79] Toledo,J.B.;Korff,A.;Shaw,L.M.;Trojanowski,J.Q.;Zhang,J. .CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer's disease[J].Acta Neuropathologica,2013(5):683-697.

[81] Montine TJ;Peskind ER;Quinn JF;Wilson AM;Montine KS;Galasko D .Increased cerebrospinal fluid F2-isoprostanes are associated with aging and latent Alzheimer's disease as identified by biomarkers.[J].Neuromolecular medicine,2011(1):37-43.

[83] Craig Schapiro R;Perrin RJ;Roe CM;Xiong C;Carter D;Cairns NJ;Mintun MA;Peskind ER;Li G;Galasko DR;Clark CM;Quinn JF;D'Angelo G;Malone JP;Townsend RR;Morris JC;Fagan AM;Holtzman DM .YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease.[J].Biological psychiatry,2010(10):903-912.

[84] Tarawneh R;D'Angelo G;Macy E;Xiong C;Carter D;Cairns NJ;Fagan AM;Head D;Mintun MA;Ladenson JH;Lee JM;Morris JC;Holtzman DM .Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease.[J].Annals of neurology,2011(2):274-285.

[85] R Tarawneh;J-M Lee;J H Ladenson;J C Morris;D M Holtzman .CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease.[J].Neurology: Official Journal of the American Academy of Neurology,2012(10):709-719.

[86] Zenzmaier C;Marksteiner J;Kiefer A .Dkk-3 is elevated in CSF and plasma of Alzheimer's disease patients.[J].Journal of Neurochemistry,2009(2):653-661.

[87] Kosicek, M.;Kirsch, S.;Bene, R.;Trkanjec, Z.;Titlic, M.;Bindila, L.;Peter-Katalinic, J.;Hecimovic, S. .Nano-HPLC-MS analysis of phospholipids in cerebrospinal fluid of Alzheimer's disease patients-a pilot study[J].Analytical and bioanalytical chemistry,2010(7/8):2929-2937.

[88] Jean-Daniel Abraham;Sophie Calvayrac-Pawlowski;Sandra Cobo;Nicolas Salvetat;Guillaume Vicat;Laurence Molina;Jacques Touchon;Bernard-Francois Michel;Franck Molina;Jean-Michel Verdier;Jeannette Fareh;Chantal Mourton-Gilles .Combined measurement of PEDF, haptoglobin and tau in cerebrospinal fluid improves the diagnostic discrimination between alzheimer s disease and other dementias[J].Biomarkers,2011(2):161-171.

[89] Guo,L.-H.;Alexopoulos,P.;Perneczky,R. .Heart-type fatty acid binding protein and vascular endothelial growth factor: Cerebrospinal fluid biomarker candidates for Alzheimer's disease[J].European archives of psychiatry and clinical neuroscience,2013(7):553-560.

[90] Vafadar-Isfahani,B.;Ball,G.;Coveney,C.;Lemetre,C.;Boocock,D.;Minthon,L.;Hansson,O.;Miles,A.K.;Janciauskiene,S.M.;Warden,D.;Smith,A.D.;Wilcock,G.;Kalsheker,N.;Rees,R.;Matharoo-Ball,B.;Morgan,K. .Identification of SPARC-like 1 protein as part of a biomarker panel for Alzheimer's disease in cerebrospinal fluid[J].Journal of Alzheimer's disease: JAD,2012(3):625-636.


DOI: http://dx.doi.org/10.1007/s12264-013-1412-1

语种: 英文   

基金This review was supported by the National Natural Science ...


期刊热词
  • + 更多
  • 字体大小